FDA approval summary: in POD1UM-303 (308 patients, first-line advanced anal squamous cell carcinoma), retifanlimab plus carboplatin–paclitaxel improved PFS vs placebo (median 9.3 vs 7.4 months; HR 0.63); interim OS not significant. Second-line single-agent ORR 14% (n=94).
RCTn = 308
Gandhy et al. FDA Approval Summary: Retifanlimab for the Treatment of Adult Patients with Metastatic or Inoperable Locally Recurrent Squamous Cell Carcinoma of the Anal Canal